APA (7th ed.) Citation

D, F., K, L., C, L., G, C., D, R., B, A., . . . CY, C. (2025). Indolent relapse after initial aggressive B-cell lymphoma: A single institution experience in the rituximab era. Leukemia & lymphoma, 66(2), 345. https://doi.org/10.1080/10428194.2024.2416563

Chicago Style (17th ed.) Citation

D, Fasser, et al. "Indolent Relapse After Initial Aggressive B-cell Lymphoma: A Single Institution Experience in the Rituximab Era." Leukemia & Lymphoma 66, no. 2 (2025): 345. https://doi.org/10.1080/10428194.2024.2416563.

MLA (9th ed.) Citation

D, Fasser, et al. "Indolent Relapse After Initial Aggressive B-cell Lymphoma: A Single Institution Experience in the Rituximab Era." Leukemia & Lymphoma, vol. 66, no. 2, 2025, p. 345, https://doi.org/10.1080/10428194.2024.2416563.